JP2011528350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528350A5 JP2011528350A5 JP2011518677A JP2011518677A JP2011528350A5 JP 2011528350 A5 JP2011528350 A5 JP 2011528350A5 JP 2011518677 A JP2011518677 A JP 2011518677A JP 2011518677 A JP2011518677 A JP 2011518677A JP 2011528350 A5 JP2011528350 A5 JP 2011528350A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- lipid compound
- compound according
- lipid
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 lipid compound Chemical class 0.000 claims 58
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000002632 lipids Chemical class 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000003857 carboxamides Chemical class 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 150000003457 sulfones Chemical group 0.000 claims 3
- 150000003462 sulfoxides Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- JFNAMHYHCCNOIS-NEUKSRIFSA-N 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfanylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCSC(CC)(CC)C(O)=O JFNAMHYHCCNOIS-NEUKSRIFSA-N 0.000 claims 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 150000001924 cycloalkanes Chemical class 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 125000002640 tocopherol group Chemical group 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical class O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- FHSRXXCRFNCZBG-JLNKQSITSA-N 1-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfanylcyclobutane-1-carboxylic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCSC1(C(O)=O)CCC1 FHSRXXCRFNCZBG-JLNKQSITSA-N 0.000 claims 1
- DLRFUJBFSPOWAI-AFSLFLIVSA-N 2-[(3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraenyl]sulfanylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCSC(CC)C(O)=O DLRFUJBFSPOWAI-AFSLFLIVSA-N 0.000 claims 1
- CJKMCXKSRWOCNR-AFSLFLIVSA-N 2-[(3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraenyl]sulfinylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCS(=O)C(CC)C(O)=O CJKMCXKSRWOCNR-AFSLFLIVSA-N 0.000 claims 1
- NAEGIDHQGAYIFF-AFSLFLIVSA-N 2-[(3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraenyl]sulfonylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCS(=O)(=O)C(CC)C(O)=O NAEGIDHQGAYIFF-AFSLFLIVSA-N 0.000 claims 1
- FOVUVFJCIMQFJK-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfanyl-2-methylpropanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCSC(C)(C)C(O)=O FOVUVFJCIMQFJK-AAQCHOMXSA-N 0.000 claims 1
- VMWSBWJJFFAPQA-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfanylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCSC(CC)C(O)=O VMWSBWJJFFAPQA-AAQCHOMXSA-N 0.000 claims 1
- UNUZTFMIJYFAPE-NEUKSRIFSA-N 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfinylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCS(=O)C(CC)(CC)C(O)=O UNUZTFMIJYFAPE-NEUKSRIFSA-N 0.000 claims 1
- LDQMFHGQNFLYJI-NEUKSRIFSA-N 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfonylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCS(=O)(=O)C(CC)(CC)C(O)=O LDQMFHGQNFLYJI-NEUKSRIFSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001258 dyslipidemic effect Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940106134 krill oil Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8080408P | 2008-07-15 | 2008-07-15 | |
| EP08160450A EP2147910A1 (en) | 2008-07-15 | 2008-07-15 | Novel lipid compounds |
| EP08160450.6 | 2008-07-15 | ||
| US61/080,804 | 2008-07-15 | ||
| PCT/NO2009/000262 WO2010008299A1 (en) | 2008-07-15 | 2009-07-13 | Novel sulphur containing lipids for use as food supplement or as medicament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528350A JP2011528350A (ja) | 2011-11-17 |
| JP2011528350A5 true JP2011528350A5 (enExample) | 2012-09-06 |
| JP5628164B2 JP5628164B2 (ja) | 2014-11-19 |
Family
ID=40419454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518677A Active JP5628164B2 (ja) | 2008-07-15 | 2009-07-13 | 補助食品としてまたは薬剤として使用するための新規硫黄含有脂質 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8759558B2 (enExample) |
| EP (2) | EP2147910A1 (enExample) |
| JP (1) | JP5628164B2 (enExample) |
| KR (2) | KR101901836B1 (enExample) |
| CN (1) | CN102159200B (enExample) |
| AU (1) | AU2009271791B2 (enExample) |
| BR (1) | BRPI0916456B8 (enExample) |
| CA (1) | CA2730958C (enExample) |
| CL (2) | CL2011000090A1 (enExample) |
| CO (1) | CO6341548A2 (enExample) |
| DK (1) | DK2313090T3 (enExample) |
| EA (1) | EA022593B1 (enExample) |
| ES (1) | ES2573977T3 (enExample) |
| HR (1) | HRP20160557T1 (enExample) |
| HU (1) | HUE029195T2 (enExample) |
| IL (1) | IL210673A (enExample) |
| IN (1) | IN2011CH01039A (enExample) |
| MA (1) | MA33083B1 (enExample) |
| MX (1) | MX2011000556A (enExample) |
| MY (1) | MY153620A (enExample) |
| NZ (2) | NZ590645A (enExample) |
| PH (1) | PH12011500113A1 (enExample) |
| PL (1) | PL2313090T3 (enExample) |
| SG (1) | SG192525A1 (enExample) |
| UA (1) | UA109252C2 (enExample) |
| VN (1) | VN28144A1 (enExample) |
| WO (1) | WO2010008299A1 (enExample) |
| ZA (1) | ZA201100666B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8741966B2 (en) | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| HRP20190732T1 (hr) * | 2009-05-08 | 2019-06-14 | Basf As | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti |
| CN102906243B (zh) | 2010-05-21 | 2014-11-12 | 米勒酿造国际有限公司 | 酒花酸及其衍生物的制备 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| KR101898610B1 (ko) | 2010-08-31 | 2018-09-14 | 서울대학교산학협력단 | ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도 |
| GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
| JP2014505017A (ja) * | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR101390589B1 (ko) * | 2012-05-30 | 2014-04-30 | 가천대학교 산학협력단 | 다이아민을 포함하는 당뇨병의 예방 또는 치료용 조성물 |
| US11351139B2 (en) | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| GB201313238D0 (en) * | 2013-07-24 | 2013-09-04 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
| GB201501144D0 (en) * | 2015-01-23 | 2015-03-11 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
| US20180104201A1 (en) | 2015-04-28 | 2018-04-19 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| AU2017329957B2 (en) | 2016-09-21 | 2020-05-07 | Avexxin As | Pharmaceutical composition |
| US10792266B2 (en) | 2017-10-23 | 2020-10-06 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| PT3720431T (pt) | 2017-12-06 | 2024-12-05 | Basf As | Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica |
| WO2019222254A1 (en) * | 2018-05-16 | 2019-11-21 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to aging |
| JP2021525249A (ja) | 2018-05-23 | 2021-09-24 | エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． | 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法 |
| US20210290576A1 (en) * | 2018-05-23 | 2021-09-23 | Northsea Therapeutics B.V. | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP7404382B2 (ja) | 2019-03-04 | 2023-12-25 | エピトラッカー インコーポレイテッド | 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用 |
| US20220249525A1 (en) * | 2019-05-20 | 2022-08-11 | T Omega As | Fatty Acid Compounds for Prevention and Treatment of Neurodegenerative Disorders |
| WO2021124272A1 (en) * | 2019-12-19 | 2021-06-24 | Liminal Biosciences Limited | Cycloalkyl-containing carboxylic acids and uses thereof |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909554A (en) * | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
| GB1038723A (enExample) | 1962-03-26 | |||
| JPS4839001B1 (enExample) * | 1970-11-09 | 1973-11-21 | ||
| US4040781A (en) * | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
| US4032564A (en) * | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
| GB1523276A (en) | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
| US4009211A (en) * | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
| US4209410A (en) * | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
| DE2861974D1 (en) * | 1977-11-11 | 1982-09-16 | Ciba Geigy Ag | Pyridine dicarboxylic acid derivatives, their mixtures with metallic stabilisers and their use in stabilising chlorine-containing thermoplasts |
| JPS5570841A (en) * | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
| US4368190A (en) * | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| US4411808A (en) * | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
| US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
| CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
| JPH0451149A (ja) * | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| FR2663928B1 (fr) | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
| JPH0543529A (ja) * | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
| US5328952A (en) * | 1992-02-14 | 1994-07-12 | Rohm And Haas Company | Multi-stage polymer latex cement modifier and process of making |
| JP2793458B2 (ja) * | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
| JP2755279B2 (ja) * | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
| AU7044894A (en) * | 1993-06-10 | 1995-01-03 | University Of North Carolina At Chapel Hill, The | (phospho)lipids for combatting hepatitis b virus infection |
| JP3110918B2 (ja) * | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| DK70295A (da) * | 1994-07-01 | 1996-01-02 | Ciba Geigy Ag | Titan- og zirkonium-komplekser af carboxylsyrer som korrosionsinhibitorer |
| KR100463709B1 (ko) * | 1994-10-13 | 2005-08-04 | 위민스 앤드 칠드런스 호스피털 애드레이드 | 변형된불포화지방산 |
| US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| FR2741619B1 (fr) * | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
| US6262119B1 (en) | 1996-04-12 | 2001-07-17 | Peptide Technology Limited | Methods of treating immunopathologies using polyunsaturated fatty acids |
| US6060515A (en) * | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
| WO1999058120A1 (en) * | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| FR2786187B1 (fr) * | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
| FR2792312B1 (fr) * | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
| EP1183074A1 (en) | 1999-06-01 | 2002-03-06 | University Of Texas Southwestern Medical Center | Substituted biaryl ether compounds |
| US6723717B1 (en) * | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
| NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
| EP1458354A1 (en) * | 2001-12-21 | 2004-09-22 | 3M Innovative Properties Company | Medicinal aerosol formulations comprising ion pair complexes |
| GB2383355A (en) * | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
| MXPA04007382A (es) * | 2002-01-31 | 2004-10-11 | Tfl Ledertechnik Gmbh | Composiciones y su uso para impartir repelencia al agua a cuero o pieles, textiles y otros materiales fibrosos. |
| EP1551228B1 (en) * | 2002-06-13 | 2012-10-03 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| AU2003278602C1 (en) | 2002-06-20 | 2010-08-12 | Pronova Biopharma Norge As | Sulfur-containing phospholipid derivatives |
| FR2845991B1 (fr) * | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
| US8372430B2 (en) * | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| US20060247458A1 (en) * | 2003-02-28 | 2006-11-02 | Shogo Yamamoto | Process for the production of optically active compounds having substituents at the 2-position |
| DE10326303A1 (de) * | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| EP1718602A4 (en) | 2004-01-30 | 2007-12-12 | Peplin Biolipids Pty Ltd | THERAPEUTIC AND CARRIER MOLECULES |
| JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
| JP2008532971A (ja) | 2005-03-08 | 2008-08-21 | チバ ホールディング インコーポレーテッド | 特定のホスホネートにより被覆された金属酸化物ナノ粒子 |
| JP5337479B2 (ja) * | 2005-05-04 | 2013-11-06 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 新規化合物 |
| WO2007116027A1 (en) | 2006-04-12 | 2007-10-18 | Unilever Plc | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
| EP1849449A1 (en) * | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
| US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| AU2007249827A1 (en) * | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| EP2094640A4 (en) * | 2006-11-01 | 2015-05-20 | Pronova Biopharma Norge As | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR) |
| WO2008053340A1 (en) * | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
| CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
| DE102007017179A1 (de) | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
| US8741966B2 (en) * | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
| LT2315740T (lt) | 2008-07-08 | 2018-02-26 | Catabasis Pharmaceuticals, Inc. | Acetilinti riebalų rūgščių salicilatai ir jų panaudojimas |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| HRP20190732T1 (hr) * | 2009-05-08 | 2019-06-14 | Basf As | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti |
| IN2012DN02661A (enExample) * | 2009-09-01 | 2015-09-11 | Catabasis Pharmaceuticals Inc | |
| CN102822141A (zh) * | 2010-01-20 | 2012-12-12 | 普罗诺瓦生物医药挪威公司 | 水杨酸脂肪酸衍生物 |
| JP2014505017A (ja) | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
| WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
| WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
-
2008
- 2008-07-15 EP EP08160450A patent/EP2147910A1/en not_active Withdrawn
-
2009
- 2009-07-13 HU HUE09798181A patent/HUE029195T2/en unknown
- 2009-07-13 JP JP2011518677A patent/JP5628164B2/ja active Active
- 2009-07-13 UA UAA201101386A patent/UA109252C2/ru unknown
- 2009-07-13 CA CA2730958A patent/CA2730958C/en active Active
- 2009-07-13 CN CN200980136136.2A patent/CN102159200B/zh active Active
- 2009-07-13 MY MYPI2011000208A patent/MY153620A/en unknown
- 2009-07-13 MX MX2011000556A patent/MX2011000556A/es active IP Right Grant
- 2009-07-13 NZ NZ590645A patent/NZ590645A/xx unknown
- 2009-07-13 KR KR1020177020879A patent/KR101901836B1/ko active Active
- 2009-07-13 BR BRPI0916456A patent/BRPI0916456B8/pt active IP Right Grant
- 2009-07-13 HR HRP20160557TT patent/HRP20160557T1/hr unknown
- 2009-07-13 EP EP09798181.5A patent/EP2313090B1/en active Active
- 2009-07-13 SG SG2013054135A patent/SG192525A1/en unknown
- 2009-07-13 KR KR1020117003422A patent/KR20110031497A/ko not_active Ceased
- 2009-07-13 NZ NZ601501A patent/NZ601501A/en unknown
- 2009-07-13 AU AU2009271791A patent/AU2009271791B2/en active Active
- 2009-07-13 DK DK09798181.5T patent/DK2313090T3/en active
- 2009-07-13 EA EA201170193A patent/EA022593B1/ru not_active IP Right Cessation
- 2009-07-13 VN VN201100380A patent/VN28144A1/vi unknown
- 2009-07-13 MA MA33613A patent/MA33083B1/fr unknown
- 2009-07-13 US US13/054,212 patent/US8759558B2/en active Active
- 2009-07-13 PL PL09798181.5T patent/PL2313090T3/pl unknown
- 2009-07-13 PH PH12011500113A patent/PH12011500113A1/en unknown
- 2009-07-13 WO PCT/NO2009/000262 patent/WO2010008299A1/en not_active Ceased
- 2009-07-13 ES ES09798181.5T patent/ES2573977T3/es active Active
-
2011
- 2011-01-14 CL CL2011000090A patent/CL2011000090A1/es unknown
- 2011-01-16 IL IL210673A patent/IL210673A/en active IP Right Grant
- 2011-01-26 ZA ZA2011/00666A patent/ZA201100666B/en unknown
- 2011-02-11 CO CO11016595A patent/CO6341548A2/es not_active Application Discontinuation
- 2011-02-14 IN IN1039CH2011 patent/IN2011CH01039A/en unknown
-
2014
- 2014-04-28 US US14/263,793 patent/US20140316002A1/en not_active Abandoned
-
2016
- 2016-02-10 US US15/040,260 patent/US20170029368A1/en not_active Abandoned
-
2018
- 2018-04-26 CL CL2018001111A patent/CL2018001111A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528350A5 (enExample) | ||
| JP5843755B2 (ja) | 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸 | |
| HRP20160557T1 (hr) | Novi lipidi koji sadrže sumpor za uporabu kao dodatak prehrani ili kao lijek | |
| RU2509071C2 (ru) | Новые липидные соединения | |
| JP2010508262A5 (enExample) | ||
| JP2012526094A5 (enExample) | ||
| CN101535238A (zh) | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 | |
| KR102265409B1 (ko) | 지질 화합물을 이용한 치료방법 | |
| JP5552314B2 (ja) | 新規脂質化合物 | |
| JP2011503057A5 (enExample) | ||
| JP2010509204A5 (enExample) | ||
| JP2011502113A (ja) | 新規のｄｈａ誘導体およびその医薬品としての用途 | |
| EP2248798A1 (en) | Novel lipid compounds | |
| RU2507193C2 (ru) | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) | |
| HK1170722B (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| HK1170722A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| JPWO2019224602A5 (enExample) | ||
| AU2013205154A1 (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |